4.3 Article

Association of serum CTRP9 levels with cardiac autonomic neuropathy in patients with type 2 diabetes mellitus

期刊

JOURNAL OF DIABETES INVESTIGATION
卷 12, 期 8, 页码 1442-1451

出版社

WILEY
DOI: 10.1111/jdi.13495

关键词

C1q TNF‐ related protein 9; Cardiac autonomic neuropathy; Type 2 diabetes

资金

  1. National Natural Science Foundation of China [81970705]
  2. Central Plains Thousand Talents Plan [204200510026]
  3. Overseas Research and Study Program for Talents in Health Science and Technology of Henan Province [2018078, 2018098]
  4. Project of Scientific Research on Traditional Chinese Medicine of Henan Province [20-21ZY2304]

向作者/读者索取更多资源

This study found that serum CTRP9 levels in patients with type 2 diabetes mellitus were associated with the prevalence and severity of cardiac autonomic neuropathy (CAN), serving as a reliable biomarker for exploring CAN in these patients.
Aims Cardiac autonomic neuropathy (CAN) is a serious complication of diabetes and is associated with adipokines. The C1q tumor necrosis factor-related protein 9 (CTRP9) is a newly discovered adipokine. This study aimed to evaluate the association of serum CTRP9 levels with the prevalence and severity of CAN in patients with type 2 diabetes mellitus. Materials and Methods We enrolled 262 patients (aged >= 18 years) with type 2 diabetes mellitus into this study. Standard cardiovascular autonomic reflex tests (CARTs) were used to assess CAN and patients were divided into three groups accordingly: a non-CAN group, an early CAN group, and a definite CAN group. Serum CTRP9 levels were measured by enzyme-linked immunosorbent assay, and the tertiles were calculated. Results Serum CTRP9 levels decreased significantly in the early CAN and definite CAN groups (P < 0.05). The percentage of definite CAN was the highest at the minimum tertile of serum CTRP9 level (T1; P < 0.05). Additionally, serum CTRP9 levels were negatively correlated with age, DM duration, hemoglobin A1c (HbA1c), and fasting plasma glucose (FPG) while positively correlated with high-density lipoprotein cholesterol (HDL; P < 0.05). The level of CTRP9 was also significantly associated with the four indexes of CARTs (P < 0.05). Furthermore, CTRP9 was a protective factor for definite CAN (P < 0.05). Compared with the maximum tertile (T3) of the serum CTRP9 levels, a decreased level of serum CTRP9 in T1 significantly increased the prevalence ratio of definite CAN in patients with type 2 diabetes mellitus (P < 0.05). Conclusion Serum CTRP9 levels were independently associated with definite CAN. CTRP9 represents a reliable biomarker for exploring CAN in patients with type 2 diabetes mellitus.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据